Healthcare
JD Health International Inc.(JDHIF)
Live Price
Offline$5.85
+0.00% today
1Y Change
+81.11%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $126.79B
- Revenue Growth
- +23.0%
- EPS Growth
- +27.3%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
JD Health International Inc. (JDHIF) is a Healthcare stock with a market cap of $126.79B and listed on OTC. The stock last traded around $5.85 and up 81.1% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +23.0%, EPS growth of +27.3%, a dividend yield of 0.0%. What stands out right now is revenue +23.0%, EPS +27.3%, free cash flow -100.0% with operating margin 5.3% and ROIC 5.6%. Valuation is more restrained than many high-expectation growth names at P/E 23.8 and price/sales 1.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines JDHIF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+23.0% vs +7.6% peer median
Operating Margin
Below sector median
+5.3% vs +19.4% peer median
P/E
Below sector median
23.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Mar 5, 2026 with revenue ahead of estimates by +2.1%.
The operating story is still moving forward
Revenue is running at +23.0% and EPS at +27.3%, with operating margin around 5.3%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 13, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 5, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Mar 6, 2025 | +6.7% | +0.0% | +0.0% | +94.1% |
2024 Aug 15, 2024 | -2.2% | +0.0% | +0.0% | +94.1% |
Benchmark Edge
JDHIF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
JDHIF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
JDHIF Max Drawdown
-33.14%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for JDHIF and SPY.
Company Overview
JD Health International Inc.
Other OTC
JD Health International Inc., an investment holding company, operates an online healthcare platform in the People's Republic of China. It offers pharmaceutical and healthcare products, including OTC drugs, prescription drugs, and medical devices and supplies, as well as health supplements and tonics through direct selling and an online retail pharmacy network. The company also provides online healthcare services, online consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services; health management and intelligent healthcare solutions, as well as technical and advertising services. In addition, it offers access to medical checkups, medical aesthetics, vaccination appointments, dental care services, and nucleic acid testing tests. The company was incorporated in 2018 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.
- Leadership
- Cao Dong
- IPO Date
- Dec 17, 2020
- Employees
- 3.6k
- Street Address
- Jingdong Headquarters
- Mailing
- Beijing, 101111
- Region
- Beijing, CN
- Reporting Currency
- USD
- Investor Line
- +86 10 8911 8888
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 23.8
- EV/EBITDA
- 23.1
- Price/Sales
- 1.7
- Price/Book
- 2.1
Growth
- Revenue
- +23.0%
- EPS
- +27.3%
- Free Cash Flow
- -100.0%
Profitability
- Gross Margin
- 24.8%
- Operating Margin
- 5.3%
- Net Margin
- 7.3%
- ROE
- 9.0%
- ROIC
- 5.6%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 2.72
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.